Authors: Ana María García Vicente Miguel Ángel Cruz Mora Antonio Alberto León Martín María del Mar Muñoz Sánchez Fernanda Relea Calatayud Ober Van Gómez López Ruth Espinosa Aunión Ana Gonzalez Ageitos Ángel Soriano Castrejón
Publish Date: 2014/08/20
Volume: 35, Issue: 11, Pages: 11613-11620
Abstract
The purpose of the present study is to explore the relation between glycolytic metabolism assessed by 18Ffluoro2deoxydglucose positron emission tomography/computed tomography 18FFDG PET/CT and final neoadjuvant chemotherapy NC response in locally advanced breast tumors Of women with breast cancer 126 were prospectively evaluated All patients underwent 18FFDG PET/CT previous to NC Standard uptake value SUV max was calculated in the primary tumor After NC residual primary tumor specimen was histopathologically classified according to Miller and Payne tumor regression grades TRG from G1 to G5 and in response groups as good responders G4 or G5 partial responders G2 or G3 and nonresponders G1 Furthermore residual lesions were classified following a binary assessment as responders G4 or G5 and nonresponders the rest of cases The relationship between SUV max with TRG and response groups was evaluated Of tumors 127 were assessed a patient had bilateral breast lesions TRG were as follows G1 27 G2 27 G3 32 G4 11 and G5 30 Fortyone were classified as good responders 59 as partial responders and 27 as nonresponders For the binary assessment 41 lesions were classified as responders and 86 as nonresponders We found statistical differences p = 002 between the mean SUV max and TRG with greater SUV values for G5 compared to the other TRG Good responders showed greater mean SUV max ± SD compared to partial responders and nonresponders 1051 ± 664 for good responders 694 ± 581 for partial responders and 523 ± 276 for nonresponders p = 0001 Baseline tumor metabolism assessing by FDG PET/CT was associated with the final histopathologic status after neoadjuvant chemotherapy with greater SUV max values for good responders compared to the less responder cancers
Keywords: